Navigation Links
Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Date:11/1/2007

utics:

Alpha 4 Beta 2 NNR Agonist Program

ABT-089 is a partial and selective NNR agonist, which targets the Alpha 4 Beta 2 NNR subtype. It has demonstrated efficacy in preclinical models of attention, learning and memory deficits. It also has demonstrated efficacy in improving the core symptoms of attention-deficit hyperactivity disorder in adults. ABT-089 is currently in Phase II clinical trials for adult attention-deficit hyperactivity disorder and is being studied for other cognitive diseases.

ABT-894 is an NNR agonist, which targets the Alpha 4 Beta 2 NNR subtype. It has demonstrated efficacy in multiple preclinical animal models of neuropathic pain and nociceptive pain with and without an inflammatory component. ABT-894 exhibits high affinity for and full functional efficacy at the Alpha 4 Beta 2 NNR subtype. Similar to other NNR agonists, it also has demonstrated a cognitive enhancing profile in pre-clinical models of cognition. ABT-894 is currently in Phase II clinical trials for adult attention-deficit hyperactivity disorder and diabetic neuropathic pain. This compound was discovered in collaboration with NeuroSearch.

Alpha 7 NNR Agonist Program

ABT-107 promises to be a potent and selective NNR agonist, which targets the Alpha 7 NNR subtype. It has demonstrated efficacy in in vivo studies that model memory consolidation, social recognition memory, working memory, and sensory gating deficits, which are domains of cognition negatively impacted in Alzheimer's disease and schizophrenia. ABT-107 is currently in Phase I clinical trials for a variety of central nervous system disorders. This compound was discovered in collaboration with NeuroSearch.

D3 Receptor Antagonist Program

In addition to the focus on NNR research, Abbott has an aggressive pre-clinical and clinical program evaluating selective D3 receptor antagonists. D3 receptors are expressed in brain regions associated with schizophrenia, and most current antipsych
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pharmacia may take 51.5 percent Abbott stake
2. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
3. Abbott’s Laboratories R&D Capabilities Questione
4. Abbott Receives CE Mark Certification
5. Abbott to Subsidize Price of HIV Drug
6. Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt
7. Abbotts Humira(r) (Adalimumab) Gets Approval by EU for Crohns Disease Treatment
8. Tony Abbott Confident Of Australias Vote For Performance Not Promise
9. Abbotts RealTime Hepatitis B Viral Load Test Receives CE Marking in Europe
10. AIDS Foundation Lauds Brazil for Negotiating Price Cut on Abbotts Kaletra
11. Researchers urge caution in using ear tube surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Supply & Demand Chain Executive Magazine has ... Know” in the supply chain industry, and we are ... team were included on this year’s list! Russ King ... due to their hard work, their commitment to excellence, ... resolving client needs and challenges. , Russ ...
(Date:3/5/2015)... 05, 2015 Dr. Jonathan Glashow a ... ) has been named by Castle Connolly ... area. Dr. Glashow has been selected by Castle Connolly ... the top specialty care doctors in the tri-state metropolitan ... Connolly program, which carefully screens and selects doctors through ...
(Date:3/5/2015)... As a result of the American ... Clearstream, LLC ’s products, services and company philosophies, ... products—led by their mPulse Hand Sanitizer—fits the core ... The AAPA—which represents a profession comprising than 100,000 ... specialties in the U.S.—advocates and educates on behalf ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Today, ... now running on 100% pollution-free electricity through a ... , As an Arcadia Power Clean Energy ... (EPA) Green Power Partnership requirements, joining national brands ... also purchase clean energy. Earth Source Organics joins ...
(Date:3/5/2015)... Park, California (PRWEB) March 05, 2015 ... (JCAP) last week released a special issue ... in the field of PANDAS (Pediatric Autoimmune Neuropsychiatric ... Neuropsychiatric Syndromes), an autoimmune reaction triggered by infections ... lyme, which result in inflammation of the child's ...
Breaking Medicine News(10 mins):Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3
... has been found that elders in hospitals and care homes are ... this, many of them are said to be in hunger// for ... Ivan Lewis. ,Commencing the ‘Dignity for older people’ campaign ... people should be thoroughly understood. When the food is kept far ...
... Pennsylvania School of Medicine have described a new type ... the patient's thoughts, providing two-way signaling for motor control ... at a junction now of developing a new approach ... Smith, MD, Professor of Neurosurgery and Director of the ...
... Scientists have unlocked the secrets of a deadly superbug that attacks ... ,The news is a vital first step in attempts to ... resistant to current antibiotic treatments. ,Already responsible for ... stages of an epidemic that could result in a massive death ...
... study, published in the March 1, 2007 issue of CANCER, ... termination of this highly effective breast cancer drug may negatively ... that over one third of women have ceased tamoxifen treatment. ... quarter of women treated for breast cancer stop tamoxifen within ...
... traits shape up in natural populations,// but one is led ... Two theories have tried to address this challenge – the ... ,The theory of hitchhiking has indicated that genes ... in natural populations when they "hitch a ride" with healthier ...
... whatever the color”, says Dr.Clive Anderson, consultant dermatologist and ... address is part of a move to get Jamaicans ... of the island’s youth resort to bleaching or lightening ... ,Government health officials plan to launch a ...
Cached Medicine News:Health News:New Ideas on Developing Thought-Controlled Artificial Limbs 2Health News:Tamoxifen Discontinuation Rates Surprisingly High 2Health News:The Evolution of Costly Traits 2
(Date:3/5/2015)... Germany , March 5, 2015 ... today announced that the foundation has made a ... CureVac, a leading clinical-stage biopharmaceutical company specializing in ... the foundation will also provide separate funding for ... CureVac,s proprietary messenger RNA (mRNA) platform. In addition, ...
(Date:3/5/2015)... 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... ended January 31, 2015 on Thursday, March 12 before the ... results at 11:00 AM ET. To participate ... 10 minutes before the beginning of the call. If you ... will be available from Thursday, March 12, 2015 through midnight ...
(Date:3/5/2015)... March 5, 2015   AMC Health , ... recognized for improving the effectiveness and efficiency of ... Robert Anazagasty and Jared Wilstead ... Vice President, Strategic Client Development, and Wilstead will ... support AMC Health,s commitment to accelerating the adoption ...
Breaking Medicine Technology:The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 3
... Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), a ... Board of Directors has approved the payment of a ... of 2012.  Zimmer,s Board of Directors also has authorized a ... opportunity to initiate a quarterly dividend results from our ...
... Dec. 19, 2011  Valeant Pharmaceuticals International, Inc. (NYSE: ... that effective December 16, 2011, the company completed ... unit of Sanofi (EURONEXT: SAN and NYSE: SNY). ... Valeant Pharmaceuticals International, Inc. (NYSE/TSX: ...
Cached Medicine Technology:Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program 2Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: